drugset / Trial / NCT00246402

Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

NCT00246402

RandomizedDouble-blindPrevention

Summary

The purpose of this study is to test whether chronic administration of the drug acipimox will improve hyperlipidemia and insulin sensitivity among HIV infected patients experiencing highly active antiretroviral therapy (HAART) associated metabolic disturbances.

Timeline

Start
2002-09
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Acipimox Small molecule 250 mg